Tolcapone in elderly patients with Parkinson's disease: A prospective open-label multicenter non-interventional trial

Archives of Gerontology and Geriatrics

Volumn 49, Issue 1, 2009, Pages

  Ebersbach, Georg ^a   Storch, Alexander ^b  

^a Movement Disorder Clinic   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Catechol O methyltransferase (COMT) inhibitor; Geriatric patients; Parkinson's disease; Tolcapone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; TOLCAPONE;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BONE DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EDEMA; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; STOMACH DISEASE; TREATMENT OUTCOME; URINE COLOR; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOPHENONES; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; PROSPECTIVE STUDIES;

EID: 67349084110     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2008.08.004     Document Type: Article

References (17)

1. Agid, Y., for the Tolcapone Study Group, 1999. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov. Disord. 14, 38-44.
2. Agid, Y., for the Entacapone to Tolcapone Switch Study Investigators, 2006. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov. Disord. 22, 14-19.
3. Assal F., Spahr L., Hadengue A., Rubbia-Brandt L., and Burkhard P.R. Tolcapone and fulminant hepatitis. Lancet 352 (1998) 958
4. Baas H., Beiske A.G., Ghika J., Jackson M., Oertel W.H., Poewe W., and Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating Parkinsonian patients. J. Neurol. Neurosurg. Psychiatry 63 (1997) 421-428
5. Brooks D.J. Safety and tolerability of COMT inhibitors. Neurology 62 (2004) S39-S46
6. Eggert K.M., Deuschl G., Gasser T., Oertel W.H., Arnold G., Baas H., Mehdorn H.M., Przuntek W., Reichmann H., Riederer P., Spieker S., and Trenkwalder C. Leitlinie Parkinson-syndrome. In: Diener H.C. (Ed). Leitlinien für Diagnostik und Therapie in der Neurologie. (2005), Georg Thieme Verlag, Stuttgart, Germany 48-71 (in German)
7. Factor S.A., Molho E.S., Feustel P.J., Brown D.L., and Evans S.M. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol. 24 (2001) 295-299
8. Jankovic J. Progression of Parkinson disease: are we making progress in charting the course?. Arch. Neurol. 62 (2005) 351-352
9. Koller W., Lees A., Doder M., and Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 16 (2001) 858-866
10. Kumar N., Van Gerpen J.A., Bower J.H., and Ahlskog J.E. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov. Disord. 20 (2005) 342-344
11. Lees A.J. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday. Mov. Disord. 22 (2007) S327-S334
12. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.X., Cote L.J., and Stern Y. A population-based investigation of Parkinson's disease with and without dementia relationship to age and gender. Arch. Neurol. 49 (1992) 492-497
13. Onofrij M., Thomas A., Iacono D., Di I.A., and Bonanni L. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. 46 (2001) 11-16
14. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., Hallett M., Miyasaki J., Stevens J., and Weiner W.J. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
15. Poewe W. The role of COMT inhibition in the treatment of Parkinson's disease. Neurology 62 (2004) S31-S38
16. Rajput A.H., Martin W., Saint-Hilaire M.H., Dorflinger E., and Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 50 (1997) S54-S59
17. Shulman L.M., Minagar A., Rabinstein A., and Weiner W.J. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov. Disord. 15 (2000) 664-668